- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Early breast cancer
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Trastuzumab emtansine – November 2019
Trastuzumab emtansine: Powder for I.V. infusion 100 mg, Powder for I.V. infusion 160 mg; Kadcyla®
Last updated
6 March 2020